The Lawyer’s new China Elite report contains the most detailed research available on the PRC legal market and contains unparalleled insight into the country's leading law firms. They vary in size, practice focus and geographic coverage, but they all share one common quality – ambition... Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Willkie Farr & Gallagher has claimed its first instruction from pharmaceutical giant Sanofi-Aventis, two years after advising shareholder Total on the E57.7bn (£38.6bn) merger that formed the company.
Paris-based partner Laurent Faugérolas led the team advising Sanofi on the disposal of its stake in chemicals firm Rhodia to BNP Paribas.
The company had picked up the shares, worth E183m (£122.7m) when Sanofi- Synthélabo and Aventis merged in early 2004. Rhodia was a legacy from the 1999 merger between Hoechst and Rhône-Poulenc that created Aventis.
Skadden Arps Slate Meagher & Flom partner Pierre Servan-Schreiber represented BNP on the transaction, which saw the bank sell the shares in a private placement immediately after acquiring the stake.
Rhodia was not represented during the transaction.